A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data
Received 27 April 2017
Accepted for publication 12 July 2017
Published 26 August 2017 Volume 2017:8 Pages 149—155
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor David B Price
David M Kern,1 John J Barron,1 Bingcao Wu,1 Alex Ganetsky,2 Vincent J Willey,1 Ralph A Quimbo,1 Michael J Fisch,3 Joseph Singer,1 Ann Nguyen,4 Ronac Mamtani5
1Health Economics and Outcomes Research, HealthCore, Inc, Wilmington, DE, 2Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Medical Oncology, AIM Specialty Health, Chicago, IL, 4Oncology Solutions, Anthem, Inc, Indianapolis, IN, 5Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
Background: Data from a Cancer Care Quality Program are directly integrated with administrative claims data to provide a level of clinical detail not available in claims-based studies, and referred to as the HealthCore Integrated Research Environment (HIRE)-Oncology data. This study evaluated the validity of the HIRE-Oncology data compared with medical records of breast, lung, and colorectal cancer patients.
Methods: Data elements included cancer type, stage, histology (lung only), and biomarkers. A sample of 300 breast, 200 lung, and 200 colorectal cancer patients within the HIRE-Oncology data were identified for medical record review. Statistical measures of validity (agreement, positive predictive value [PPV], negative predictive value [NPV], sensitivity, specificity) were used to compare clinical information between data sources, with medical record data considered the gold standard.
Results: All 300 breast cancer records reviewed were confirmed breast cancer, while 197 lung and 197 colorectal records were confirmed (PPV =0.99 for each). The agreement of disease stage was 85% for breast, 90% for lung, and 94% for colorectal cancer. The agreement of lung cancer histology (small cell vs non-small cell) was 97%. Agreement of progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2 status biomarkers in breast cancer was 92%, 97%, and 92%, respectively; epidermal growth factor receptor and anaplastic lymphoma kinase agreement in lung was 97% and 92%, respectively; and agreement of KRAS status in colorectal cancer was 95%. Measures of PPV, NPV, sensitivity, and specificity showed similarly strong evidence of validity.
Conclusion: Good agreement between the HIRE-Oncology data and medical records supports the validity of these data for research.
Keywords: validation, administrative claims, breast cancer, lung cancer, colorectal cancer, oncology
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]